2. Neuronal Signaling
  3. α-synuclein
  4. Senkyunolide A

Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis.

For research use only. We do not sell to patients.

CAS No. : 63038-10-8

Size Price Stock Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Liquid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Senkyunolide A Related Antibodies

Top Publications Citing Use of Products

    Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542.  [Abstract]

    The cell viability of chondrocytes treated with different concentrations of Senkyunolide A (SenA) (0, 20, 40, 80 and 160 μg/mL) was measured by MTT assay.

    Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542.  [Abstract]

    Senkyunolide A (SenA) (20, 40, 80 μg/mL) inhibited the expression of catabolic marker proteins (MMP13, ADAMTS4/5) in IL-1β stimulated chondrocytes.

    Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542.  [Abstract]

    Senkyunolide A (SenA) (20, 40, 80 μg/mL) promoted cell proliferation of IL-1b-stimulated chondrocytes.

    Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542.  [Abstract]

    Senkyunolide A (SenA) (20, 40, 80 μg/mL) inhibited cell apoptosis of IL-1b-stimulated chondrocytes.

    Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542.  [Abstract]

    H&E staining was used to observe the pathological changes of knee joint treated with Senkyunolide A (SenA) (20, 40 mg/kg, i.p.).

    View All α-synuclein Isoform Specific Products:

    View All Isoforms
    α-synuclein α-synuclein Aggregation α-synuclein/CHMP2B

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis[1][2][3][4][5].

    IC50 & Target[4]

    α-synuclein

     

    In Vitro

    Senkyunolide A (0-2.5 μg/mL; 24 h) inhibits the proliferation of HT-29 and CCD-18Co cells with IC50 of 10.4 μM and 20.95 μM, respectively [1].
    Senkyunolide A (100 μM; 6 h) inhibits the high expression of CD137 in TNF-α treated MAECs cells[2].
    Senkyunolide A (0.125-0.5 μg/mL; 24-72 h) improves cell viability, decreases apoptosis, LDH release, α-syn expression and PP2P phosphorylation in PC12 cells treated with corticosterone (HY-B1618)[3].
    Senkyunolide A (20-80 μg/mL; 48 h) promotes cell proliferation and inhibits cell apoptosis in IL-1β-treated chondrocytes, and inhibits cell inflammation by blocking the NLRP3 signaling pathway[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Senkyunolide A Related Antibodies

    Western Blot Analysis[4]

    Cell Line: Chondrocytes
    Concentration: 20, 40 and 80 μg/mL
    Incubation Time: 48 h
    Result: Decreased the levels of NLRP3, ASC and caspase-1.
    Reduced the levels of TNF-a, IL-6 and IL-18.
    Parmacokinetics
    Species Dose Route Note T1/2 Plasma Concentration AUC Vd Clearance (CL) Tmax Bioavailability
    Rat[5] 20 mg/kg i.v. pure 0.65 h 19.67 mg/L 2.81 mg·h/L 6.74 L/kg 7.20 L/h/kg / /
    Rat[5] 5.8 mg/kg i.v. ext 0.69 h 4.86 mg/L 0.95 mg/h/L 7.12 L/kg 9.17 L/h/kg / /
    Rat[5] 50 mg/kg i.p. / 0.67 h 17.6 mg/L 5.29 mg/h/L 9.98 L/kg 10.92 L/h/kg 0.04 h 75.3 %
    In Vivo

    Senkyunolide A (20-40 mg/kg; Intraperitoneal injection; 1 week) shows improvement in the mouse model of osteoarthritis[4].
    Pharmacokinetic Analysis in Rats[5]

    Route Dose (mg/kg) Tmax (h) Cmax (mg/L) t1/2 (h) AUC0→∞ (mg/h per liter) Vd/F (L/kg) CL/F (L/h per kilogram) F (%)
    i.v. 20 (pure) / 19.67 0.65 2.81 6.74 7.20 /
    i.v. 7.65 (ext)* / 4.86 0.69 0.95 7.12 9.17 /
    i.p. 50 0.04 17.60 0.67 5.29 9.98 10.92 75.3
    i.p. 100 0.04 31.01 0.99 10.65 13.78 9.72 75.8
    p.o. 100 0.21 1.66 0.52 1.11 68.97 94.81 7.9
    *The herbal extract containing 7.65% of senkyunolide A was given at a dose of 100 mg/kg.

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male C57BL/6 mice (200-220 g) with osteoarthritis[4]
    Dosage: 20 and 40 mg/kg
    Administration: Intraperitoneal injection (i.p.); 1 week
    Result: Alleviated articular cartilage destruction by inhibiting NLRP3 signalling pathway.
    Significantly reduced the levels of NLRP3, ASC and caspase-1.
    Molecular Weight

    192.26

    Formula

    C12H16O2
    CAS No.
    Appearance

    Liquid (Density: 1.1±0.1 g/cm3)

    Color

    Colorless to light yellow

    SMILES

    O=C1O[C@@H](CCCC)C2=C1C=CCC2
    Structure Classification
    Initial Source
    Shipping

    Shipping with dry ice.
    Storage

    -80°C, protect from light, stored under nitrogen
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (520.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.2013 mL 26.0067 mL 52.0134 mL
    5 mM 1.0403 mL 5.2013 mL 10.4027 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (13.00 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (13.00 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.92%

    SDS (393 KB)

    COA (252 KB) HNMR (252 KB) LCMS (265 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 5.2013 mL 26.0067 mL 52.0134 mL 130.0336 mL
    5 mM 1.0403 mL 5.2013 mL 10.4027 mL 26.0067 mL
    10 mM 0.5201 mL 2.6007 mL 5.2013 mL 13.0034 mL
    15 mM 0.3468 mL 1.7338 mL 3.4676 mL 8.6689 mL
    20 mM 0.2601 mL 1.3003 mL 2.6007 mL 6.5017 mL
    25 mM 0.2081 mL 1.0403 mL 2.0805 mL 5.2013 mL
    30 mM 0.1734 mL 0.8669 mL 1.7338 mL 4.3345 mL
    40 mM 0.1300 mL 0.6502 mL 1.3003 mL 3.2508 mL
    50 mM 0.1040 mL 0.5201 mL 1.0403 mL 2.6007 mL
    60 mM 0.0867 mL 0.4334 mL 0.8669 mL 2.1672 mL
    80 mM 0.0650 mL 0.3251 mL 0.6502 mL 1.6254 mL
    100 mM 0.0520 mL 0.2601 mL 0.5201 mL 1.3003 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Senkyunolide A Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Senkyunolide A63038-10-8α-synucleinα-SynHT-29 cellsCCD-18Co cells MAECs cellsPC12 cellsChondrocytesosteoarthritis modelInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Senkyunolide A
    Cat. No.:
    HY-N0743
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.